# Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern

> **NCT05168813** · PHASE2,PHASE3 · COMPLETED · sponsor: **COVID-19 Prevention Network** · enrollment: 14237 (actual)

## Conditions studied

- SARS-CoV-2 Infection
- HIV Infections
- COVID-19

## Interventions

- **BIOLOGICAL:** Moderna mRNA-1273
- **BIOLOGICAL:** Moderna mRNA-1273.222
- **BIOLOGICAL:** Vaccine 3 Dose
- **BIOLOGICAL:** Vaccine 2 Dose

## Key facts

- **NCT ID:** NCT05168813
- **Lead sponsor:** COVID-19 Prevention Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-01
- **Primary completion:** 2024-04-19
- **Final completion:** 2024-04-19
- **Target enrollment:** 14237 (ACTUAL)
- **Last updated:** 2026-04-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05168813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05168813, "Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT05168813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*